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Purpose: To investigate the effect of a combination of carnosine and aspirin eye drops on the progression of diabetic
cataract formation induced by streptozotocin (STZ).
Methods: Rats were made diabetic with STZ. Animals in the treated groups received carnosine, aspirin, or a combination
of carnosine and aspirin as drops to the eyes. Cataract progression was monitored by slit lamp microscope and classified
into four stages. At the end of 8 weeks, the animals were killed and biochemical changes were determined. Blood and
urine glucose levels, body weights, food, and intake were also determined.
Results: About 84.4% of the rats responded to the STZ injection. There were statistically significant differences in the
stage of cataract of lenses between the untreated and the treated diabetic animals and between the combination and the
aspirin group at the 7th and 8th week. There was a significant decrease in the water-soluble protein in the diabetic groups
compared with the control group. The three treatments improved the water-soluble protein levels, and the combination
treatment had the greatest effect. The levels of thiol were remarkably decreased in the lenses of diabetic rats, except the
combination group. The specific activity of glutathione peroxidase (GPx) was increased and the activities of glutathione
reductase (GR) and catalase (CAT) were decreased in all the diabetic groups.
Conclusions: The results indicated that carnosine, aspirin, and a combination eye drops are effective against the onset
and development of diabetic cataract in rats. Most important, the effect of combination eye drops is better than aspirin
only.
Cataract  is  one  of  the  major  causes  of  blindness
worldwide. An estimated 16-20 million persons are blind from
cataract, although it is curable through cataract surgery with
appropriate correction [1-3]. At present, surgical treatment
with phacoemulsification and intraocular lens implantation
remains  the  only  proven  treatment.  This,  however,  is
associated with significant cost and is not readily available,
especially in developing countries where the prevalence of
cataract is the highest [4,5]. Besides possible complications,
an artificial lens does not have the overall optical qualities of
a normal lens [6]. Visual inconvenience worsens the quality
of life; therefore, preventive and nonsurgical approaches to
cataract treatment are highly desired due to an increase in the
number of patients, in parallel with the growth and aging of
the population [5]. It is estimated that a delay in cataract
formation of about 10 years would reduce the prevalence of
visually disabling cataract by about 45% [7].
Diabetes is one of the most important risk factors for
cataract [1,8,9] and cataractogenesis is one of the earliest
secondary  complications  of  diabetes  mellitus.  Since
extracellular glucose diffuses into the lens uncontrolled by the
hormone insulin, the lens is one of the body parts most affected
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in diabetes. Possible pathophysiological mechanisms include
non-enzymatic glycosylation (glycation) with cross linking of
proteins, and oxidative stress [4]. Multiple mechanisms have
been implicated in the development of cataract in diabetes. To
date, the exact sequence of events that leads to opacification
has not been clearly defined. Thus, the relationship of the
opacity to the initiating event may be obscure.
Many  anti-cataractogenic  agents,  such  as  aldose
reductase inhibitors, have been described so far, but owing to
lack of success in patients, no drug has yet been approved for
clinical use [10-13]. Evidence from epidemiological, in vitro,
and animal studies has accumulated to support the idea that
carnosine  and  aspirin  [14-18]  protect  against  cataract.
Carnosine is a naturally occurring, water-soluble dipeptide. It
has antioxidant and antiglycating properties, and may be a
potential therapeutic agent mainly due to its antioxidant and
antiglycating activities [18-23]. Aspirin has been shown to
reduce glycation in vitro, and in animal experiments, probably
by  acetylation  of  amino  groups,  and  it  also  may  inhibit
glycoxidation and AGE-cross-link formation [1]. Aspirin and
aspirin-like analgesics have been studied in a variety of model
systems  including  diabetic  rats  [15-18].  A  variety  of
laboratory and epidemiological evidence supports the benefits
of  aspirin-like  drugs  but  there  has  been  no  clinical  trial
specifically in patients with cataract [13,24].
Previously, the results from our studies have shown that
diabetic cataract in rats could be prevented by carnosine or
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2129aspirin eye drops, which readily penetrated into the eye after
topical administration without producing plasma drug levels
that could lead to systemic side effects [18]. On the basis of
the properties of carnosine and aspirin mentioned above, we
suspected that a combination of carnosine and aspirin eye
drops  could  be  more  effective  than  either  of  them  alone.
Therefore, the purpose of this study was to investigate whether
using eye-drops containing carnosine and aspirin together
might inhibit the progression of diabetic lens opacities better
than eye drops containing carnosine or aspirin alone.
METHODS
Materials: streptozotocin (STZ) and carnosine were obtained
from Sigma Chemical Company (Beijing, China). Sprague-
Dawley rats were provided by Animal Laboratories of the
Fourth Military Medical University (Xi’an, China). Protein
and enzyme quantification kits were obtained from Jiancheng
Biology Company (Nanjing, China). Glucotrend 2 was from
Roche Diagnositic Limited Company (Xi’an, China). Tes-
Tape was from Zhujiang Biochemistry Reagents (Guangzhou,
China). All other chemicals and solvents were of analytical
grade and were obtained from local companies.
Animals: One hundred-two male Sprague-Dawley rats, one-
month old, initially weighing 135-180 g were used in the
study. All the animals were fed standard diet ad libitum and
randomly assigned to five groups. The animals were housed
in five individual cages in a room. All the animals had free
access to drinking water. Group A rats (normal control, n=12)
received an injection of 0.02 mol/l citrate buffer (pH 4.5, 65
mg/kg body weight, intraperitoneally) as a vehicle, however,
the  experimental  groups  (Group  B–E)  received  an
intraperitoneal injection of 1% STZ in citrate buffer at a dose
of 65 mg/kg body weight. After 96 h, random blood glucose
levels were monitored. The animals having blood glucose
levels <14mmol/l were excluded from the experiment and the
rest were distributed into the following groups: B (diabetic
rats untreated, n=21), C (diabetic rats treated with carnosine
eye drops 1% only, n=17), D (diabetic rats treated with aspirin
eye drops 0.05% only, n=21), and E (diabetic rats treated
alternately with carnosine 1% and aspirin 0.05% eye drops,
n=17).
Experimental design: Carnosine eye drops (1%, pH 7.4) were
prepared  in  25  mmol/l  sodium  phosphate  buffer  (pH  7.4,
containing  2.527  g  of  sodium  dihydrogen  phosphate
dihydrate, 1.36 g of disodium phosphate dodecahydrate, and
800 ml double distilled water). Animals from group C and D
were treated respectively by instillation of 1% carnosine eye
drops, or 0.05% aspirin eye drops, one drop, twice a day for
8 weeks. Rats from group E received combined treatment by
instillation of 1% carnosine eye drops and 0.05% aspirin eye
drops  twice  a  day  alternately,  respectively  for  8  weeks.
However,  the  animals  from  group  B  only  received  the
instillation of the vehicle solution, one drop, twice a day.
Pupils  were  dilated  before  slit  lamp  examination  of
lenses. Each rat was checked for cataract every week after
streptozotocin  injection.  Initiation  and  progression  of
lenticular opacity was graded, double-blind, according to the
Oxford system [15,25]: grade 0, clear; grade 1, wide sutures;
grade 2, nuclear with opacities radiating from sutures; and
grade 3, dense nuclear without clefts. The stage of cataract
was scored according to the classification described above.
Blood was collected from the caudal end of rats for glucose
estimation with Glucotrend 2 every two weeks. Furthermore,
the food intake, water intake, urine weight (daily) and body
weights, and urine glucose (weekly) were monitored.
In  the  8th  week,  the  animals  were  killed  following
cervical  dislocation  under  ether  anesthesia,  the  eyes  were
enucleated, and the lenses were dissected separately and kept
at -70 °C until further analysis. All the biochemical parameters
were analyzed in the soluble fraction of the lens homogenate.
Biochemical estimations:
Protein  determination—Protein  concentration  was
determined by the Coomassie brilliant blue method using a
protein assay kit from Jiancheng Company (Nanjing, China)
[26,27]. Two lenses in each rat were ground in 0.9% neutral
normal saline (1:9) and homogenized by hand in the ice-water
mixture to make the 10% homogenate, and then centrifuged
(11,500× g) in Eppendorf tubes. Clear supernatant was used
for protein determination, which was carried out according to
the  method  described  with  the  kit's-
Coomassie brilliant blue method.
Thiol  (from  glutathione  [GSH]  and  protein)
determination—Thiol was measured using the dithio-bis-
nitrobenzoic  acid  (DTNB)  method  at  25  °C  and  412  nm
[28-30].  The  clear  supernatant  liquid  used  for  protein
determination  was  taken  by  suction  from  the  centrifuged
Eppendorf  tube,  and  the  thiol  content  was  determined
according to the description of kit. Thiol reacts with dithio-
dinitrobenzoic acid to give a yellow compound, which has a
high  absorption  of  light  at  412  nm  which  was  measured.
Through this colorimetric method the content of thiol in each
lens was determined.
Assay of GR activity—Glutathione reductase (GR) was
determined  using  an  assay  kit  from  Jiancheng  Company
(Nanjing, China). GR activity was measured according to the
procedure in which oxidized glutathione (GSSG) was reduced
to  GSH  catalyzed  by  GR  with  NADPH  as  cofactor.  The
decrease in the optical density at 340nm was recorded at 25
°C for 2 min. The units of enzymatic activity were calculated
using an extinction coefficient of 6.22 mM•cm-1 for NADPH.
One  unit  was  equivalent  to  the  oxidation  of  1  mmol  of
NADPH per min [31].
Assay  of  CAT  activity—Catalase  (CAT)  was
determined  using  an  assay  kit  from  Jiancheng  Company
(Nanjing,  China).  CAT  activity  in  lens  was  assayed  with
hydrogen peroxide as substrate using a method based on the
direct measurement of H2O2 decomposition. The final volume
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2130of each enzyme assay was 3 ml substrate and 20 μl supernatant
of lens homogenates. Assay was performed at 25 °C and 24
nm. Enzyme activity was expressed as units per g of protein
and  one  unit  of  CAT  activity  represented  1  mmol  H2O2
decomposed per min [32].
Assay of GPx activity—Glutathione peroxidase (GPx)
catalyzes  the  reduction  of  hydroperoxides,  including
hydrogen peroxides, by reduced glutathione and functions to
protect the cell from oxidative damage. With the exception of
phospholipid-hydroperoxide GPx, a monomer, all of the GPx
enzymes are tetramers of four identical subunits [33,34]. Each
subunit contains a selenocysteine in the active site which
participates  directly  in  the  two-electron  reduction  of  the
peroxide  substrate.  The  enzyme  uses  glutathione  as  the
ultimate electron donor to regenerate the reduced form of the
selenocysteine [33,34]. The Glutathione Peroxidase Assay Kit
measures GPx activity indirectly by a coupled reaction with
GR.  GSSG,  produced  upon  reduction  of  an  organic
hydroperoxide by GPx, is recycled to its reduced state by GR
and  NADPH.  The  oxidation  of  NADPH  to  NADP+  is
accompanied by a decrease in absorbance at 340 nm. The rate
of decrease in the A340 is directly proportional to the GPx
activity in the sample [35].
Statistical analysis: One-way ANOVA was used for testing
statistical significances between groups of data. Individual
pair differences were tested by means of Duncan’s multiple-
range  test.  Heterogeneity  of  variance  was  tested  by  the
nonparametric Mann-Whitney test. p<0.05 was considered
significant.
RESULTS
Fourteen  (14/90)  non-responders  to  STZ  (blood  glucose
measured  <14  mmol/l)  at  96  h  after  receiving  an
intraperitoneal injection were found; two rats (from Group D
and E, respectively) whose blood glucose level had fallen
below 14 mmol/l by the 3rd week and the animals that died
before the end of the experiment were all excluded, leaving
51 rats in the study.
The food (Figure 1) and water (Figure 2) intake in all the
diabetic groups increased more than that in the normal group,
although  the  normal  group's  food  and  water  intake  also
increased due to its growth, and so did the urine weight (Figure
3)  and  the  urine  glucose  (Figure  4).  The  body  weight  of
diabetic rats was much less than that of the control group rats
from  the  first  week.  The  three  treatment  groups  did  not
improve the body weight of diabetic individuals (Table 1).
There was an increase in blood glucose levels in Groups
B-E compared with Group A, and the treatment did not reverse
the changes in blood glucose levels. The results indicated that
treatment with carnosine or aspirin and combination eye drops
had no effect on the blood glucose level of STZ-induced
diabetic rats (Table 2).
All  the  lenses  in  Group  A  were  clear  and  normal
throughout  the  study.  Eight  lenses  with  an  onset  of  lens
opacification were observed at the 4th week in Group B but
the onset of lens opacification was not observed until at the
5th week in Group C–E by slit lamp examination (Figure 5).
The progression of cataract appeared slower in all the
treated  groups  (C,  D,  and  E)  compared  to  the  untreated
diabetic rats (Figure 6). According to the method of categories
reported above, the stage of cataract of lenses among the five
groups differed during the duration of the study (p<0.001,
Figure 6). Photographs of the stage of cataract from stage 0 to
stage 3 in the present study are shown in Figure 7. Moreover,
there was a statistically significant difference between the
untreated diabetic and the treated diabetic animals (p<0.05),
and between Group E and D (p<0.05) at the 7th week and 8th
week (Figure 8 and Table 3). Note that at the eighth week the
majority of lenses in the untreated diabetic rats reached stage
TABLE 1. THE EFFECT OF CARNOSINE, ASPIRIN AND A COMBINATION OF BOTH EYE DROPS ON BODY WEIGHT (G/PER ANIMAL) IN STZ-INDUCED RATS.
Group 0 week (g) 1 week (g) 2 week (g) 3 week (g) 4 week (g) 5 week (g) 6 week (g) 7 week (g)
A 158.75±9.78
(n=12)
234.17±12.94
(n=12)
280.83±17.17
(n=12)
298.33±22.19
(n=12)
346.25±25.42
(n=12)
390.00±28.20
(n=12)
430.83±46.02
(n=12)
485.42±40.53
(n=12)
B 158.33±13.24
(n=24)
158.57±23.93
(n=21)
146.00±22.63
(n=20)
149.64±28.72
(n=14)
156.15±26.78
(n=11)
165.42±30.49
(n=11)
175.00±29.07
(n=11)
174.09±29.40
(n=11)
C 162.05±11.20
(n=22)
177.06±17.24
(n=17)
172.35±16.50
(n=17)
172.50±20.45
(n=10)
174.00±21.83
(n=10)
175.00±27.89
(n=10)
176.00±30.89
(n=10)
176.50±30.28
(n=10)
D 159.09±10.65
(n=22)
171.90±22.44
(n=21)
143.33±22.55
(n=18)
152.73±12.32
(n=11)
154.09±15.14
(n=11)
156.82±20.65
(n=11)
157.27±24.94
(n=11)
158.64±24.71
(n=11)
E 155.91±12.31
(n=22)
163.82±22.19
(n=17)
169.12±22.31
(n=16)
222.86±13.18
(n=7)
215.00±8.17
(n=7)
205.71±10.18
(n=7)
200.00±17.08
(n=7)
199.29±20.70
(n=7)
The data are mean±SD. “n” was the numbers of the animals in each group every week. There was a statistically significant
difference  between diabetic rats and normal rats (B~E VS A; p<0.001) from 1 week to 7 weeks. Row A was the normal control
group, row B was the diabetic rats untreated group, row C was the diabetic rats treated with carnosine eye drops (1% only)
group, row D was the diabetic rats treated with aspirin eye drops (0.05% only) group, and row E was the diabetic rats treated
alternately with carnosine (1%) and aspirin (0.05%) eye drops group. The numbers in the 0 week column represent the data of
body weight before receiving an intraperitoneal injection.
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21313 whereas only a minority of rats in the three treated groups
reached  this  stage.  These  results  suggested  that  the
combination treatment with 1% carnosine and 0.05% aspirin
eye drops delayed the occurrence and progression of STZ-
induced diabetic cataract and the effect was better than that
with 0.05% aspirin eye drops only (Table 3). In the 8th week,
although the stage of lens opacification in Goup E was higher
Figure 1. The effect of carnosine, aspirin, and a combination of both
eye drops on food intake of each rat per day in various groups, as a
function of time, indicating that the food intake in all the diabetic
groups increased more than that in the normal group although the
normal group's food intake also increased due to its growth. Panel A
was the normal control group, panel B was the diabetic rats untreated
group, panel C was the diabetic rats treated with carnosine eye drops
(1% only) group, panel D was the diabetic rats treated with aspirin
eye drops (0.05% only) group, and panel E was the diabetic rats
treated alternately with carnosine (1%) and aspirin (0.05%) eye drops
group.
than that in Group C, no statistically significant difference was
found between them (Table 3).
In our previous studies we evaluated the safety of eye
drops by observing the extent of corneal staining [18]. In this
combination study, no further corneal staining or side effects
were noticed.
Figure 2. The effect of carnosine, aspirin, and a combination of both
eye drops on water intake of each rat per day in various groups, as a
function of time, indicating that the water intake in all the diabetic
groups increased more than that in the normal group although the
normal group's water intake also increased due to its growth. Panel A
was the normal control group, panel B was the diabetic rats untreated
group, panel C was the diabetic rats treated with carnosine eye drops
(1% only) group, panel D was the diabetic rats treated with aspirin
eye drops (0.05% only) group, and panel E was the diabetic rats
treated alternately with carnosine (1%) and aspirin (0.05%) eye drops
group.
TABLE 2. THE CHANGES OF BLOOD GLUCOSE (MMOL/L) AFTER INJECTION OF STZ.
Group 0 week (mmol/l) 1 week (mmol/l) 3 week (mmol/l) 5 week (mmol/l) 7 week (mmol/l)
A 7.642±0.8959
(n=12)
7.875±1.1250
(n=12)
7.258±0.8565
(n=12)
5.150±0.7972
(n=12)
6.842±0.8929
(n=12)
B 7.792±0.9427
(n=24)
32.719±1.5468*
(n=21)
32.586±2.6726*
(n=14)
29.025±5.3268*
(n=11)
32.391±3.015*
(n=11)
C 7.100±0.7801
(n=22)
30.759±4.1794*
(n=17)
32.042±3.5935*
(n=10)
24.920±3.1860*
(n=10)
30.490±4.535*
(n=10)
D 7.368±1.0634
(n=22)
27.040±6.3860*
(n=21)
33.118±0.6030*
(n=11)
29.345±3.7063*
(n=11)
32.027±2.867*
(n=11)
E 7.523±1.0752
(n=22)
32.612±1.6959*
(n=17)
31.470±3.7589*
(n=7)
29.200±3.5473*
(n=7)
31.257±3.147*
(n=7)
Each value is the mean± SD of results in all the animals in a given group. “n” was the numbers of the animals in each group
every  week. The asterisk indicates a p <0.001, as compared to the normal group (Group A) with the four diabetic groups (Group
B-E). There were no statistically significant differences between the four diabetic groups through the experiment. Row A was
the normal control group, row B was the diabetic rats untreated group, row C was the diabetic rats treated with carnosine eye
drops (1% only) group, row D was the diabetic rats treated with aspirin eye drops (0.05% only) group, and row E was the diabetic
rats treated alternately with carnosine (1%) and aspirin (0.05%) eye drops group. The numbers in the 0 wk column were the
data of blood glucose in the different groups before receiving an intraperitoneal injections.
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2132Protein  denaturation  has  been  considered  to  be  the
ultimate change that results in lens opacification. Therefore,
we  analyzed  the  water-soluble  protein  content  in  all  the
groups. There was a significant decrease in water-soluble
protein in group B-E compared with the control group (Table
4). The three treatments appeared to improve soluble protein
levels, and the Group E treatment appeared to provide greater
Figure 3. The effect of carnosine, aspirin, and a combination of both
eye drops on urine weight of each rat per day in various groups, as a
function of time, indicating that the urine glucose in all the diabetic
groups increased more than that in the normal group. Panel A was
the normal control group, panel B was the diabetic rats untreated
group, panel C was the diabetic rats treated with carnosine eye drops
(1% only) group, panel D was the diabetic rats treated with aspirin
eye drops (0.05% only) group, and panel E was the diabetic rats
treated alternately with carnosine (1%) and aspirin (0.05%) eye drops
group.
improvement than the others. However these differences were
not statistically significant.
Thiol levels of were decreased in the groups of diabetic
lenses. This result indicated that there was increased oxidative
Figure 4. The effect of carnosine, aspirin, and a combination of both
eye drops on stage of urine glucose of each rat per day in various
groups, as a function of time, suggesting that the progression of
cataract  appeared  slower  in  all  the  treated  groups.  These  data
indicated  that  the  treatment  delayed  the  the  onset  of  lens
opacification. Panel A was the normal control group, panel B was
the diabetic rats untreated group, panel C was the diabetic rats treated
with carnosine eye drops (1% only) group, panel D was the diabetic
rats treated with aspirin eye drops (0.05% only) group, and panel E
was the diabetic rats treated alternately with carnosine (1%) and
aspirin (0.05%) eye drops group.
TABLE 3. THE EFFECT OF CARNOSINE AND ASPIRIN DROPS ON STZ-INDUCED LENS OPACITY.
Group 0 week 1 week 2 week 3 week 4 week 5 week 6 week 7 week 8 week
A 0 (0~0)
(n=12)
0 (0~0)
(n=12)
0 (0~0)
(n=12)
0 (0~0)
(n=12)
0 (0~0)
(n=12)
0 (0~0)
(n=12)
0 (0~0)
(n=12)
0 (0~0)                  0 (0~0)
 (n=12)             (n=12)
B 0 (0~0)
(n=24)
0 (0~0)
(n=21)
0 (0~0)
(n=20)
0 (0~0)
(n=14)
0 (0~1)
(n=11)
0 (0~1)
(n=11)
1 (0~2)
(n=11)
1 (0~2)                   2 (1~3)
(n=11)              (n=11)
C 0 (0~0)
(n=22)
0 (0~0)
(n=17)
0 (0~0)
(n=17)
0 (0~0)
(n=10)
0 (0~0)
(n=10)
0 (0~1)
(n=10)
0.5 (0~2)
(n=10)
0.5 (0~2)*
(n=10)
1 (0~3)*
(n=10)
D 0 (0~0)
(n=22)
0 (0~0)
(n=21)
0 (0~0)
(n=18)
0 (0~0)
(n=11)
0 (0~0)
(n=11)
0 (0~1)
(n=11)
0.5 (0~2)
(n=11)
0.5 (0~2)*
(n=11)
2 (1~3)
 (n=11)
E 0 (0~0)
(n=22)
0 (0~0)
(n=17)
0 (0~0)
(n=16)
0 (0~0)
(n=7)
0 (0~0)
(n=7)
0 (0~1)
(n=7)
0.5 (0~2)
(n=7)
0.5 (0~2)*,#
(n=7)
1.5 (1~3)*,#
(n=7)
Values are expressed as medians (range of grades), “n” was the numbers of the animals in each group every week. Median
representation: 0, clear; 1, clear nuclear with wide sutures; 2, slight dense nuclear with opacities radiating from sutures; 3, dense
nuclear without clefts; 4, dense nuclear with clefts; 5, nuclear cataract with clefts; 6, nuclear cataract with dense radial opacities;
7, nuclear cataract with whole lens opacities. Statistical analyses were performed by using Wilcoxon Rank Sum Test. The asterisk
indicates significantly different from Group B; p<0.05 and the sharp (hash mark) indicates significantly different from Group
D; p<0.05. Row A was the normal control group, row B was the diabetic rats untreated group, row C was the diabetic rats treated
with carnosine eye drops (1% only) group, row D was the diabetic rats treated with aspirin eye drops (0.05% only) group, and
row E was the diabetic rats treated alternately with carnosine (1%) and aspirin (0.05%) eye drops group. Stage 0.5 indicates that
about half of the lenses were at stage 0 while the remainder had progressed to stage 1. Stage 1.5 indicates that about half of the
lenses were at stage 1 while the remainder had progressed to stage 2. The numbers in 0 wk column represent the data in the
lenses before receiving an intraperitoneal injection.
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2133stress in diabetic cataractous lenses. Thiol levels were higher
in  the  treated  groups  although  these  differences  were  not
statistically significant. Group E thiol levels were improved
compared with the other diabetic groups and not statistically
significant from the normal control group (Table 4). Although
the levels of thiol in Group E had not returned to normal, they
improved significantly with treatment when compared with
levels in the untreated diabetic animals.
The specific activity of GPx increased significantly in all
the diabetic groups (Table 4), but was significantly decreased
Figure 5. The effect of carnosine, aspirin and a combination of both
eye drops on STZ-induced cataract rats at the 5th week. In the
calculation of the incidence of lenses in various stages, total lenses
in a group were considered to be 100%. Panel A was the normal
control group, panel B was the diabetic rats untreated group, panel C
was the diabetic rats treated with carnosine eye drops (1% only)
group, panel D was the diabetic rats treated with aspirin eye drops
(0.05%  only)  group,  and  panel  E  was  the  diabetic  rats  treated
alternately with carnosine (1%) and aspirin (0.05%) eye drops group.
These data suggested that the combination treatment with carnosine
1%  and  aspirin  0.05%  eye  drops  delayed  the  occurrence  and
progression of STZ-induced diabetic cataract and the effect was
better than that with aspirin 0.05% eye drops only.
in treated groups compared to the untreated diabetics. The
combined treatment restored GPx levels better than aspirin
alone.
There appeared to be decreased activities of GR and CAT
in diabetes (Table 4), but there was no statistically significant
difference in activity of GR and CAT between the groups.
DISCUSSION
Cataract is the major cause of blindness and visual impairment
worldwide, and multiple factors are involved in the formation
of cataract [4,36,37]. Diabetes mellitus is one of the major risk
factors for cataract development [9]. Although, there have
been major advances in the control of hyperglycemia through
dietary  changes,  hypoglycemic  agents,  insulin,  and  islet
Figure 6. The effect of carnosine, aspirin and a combination of both
eye drops on the median stage of cataract, as a function of time. Panel
A  was  the  normal  control  group,  panel  B  was  the  diabetic  rats
untreated group, panel C was the diabetic rats treated with carnosine
eye drops (1% only) group, panel D was the diabetic rats treated with
aspirin eye drops (0.05% only) group, and panel E was the diabetic
rats treated alternately with carnosine (1%) and aspirin (0.05%) eye
drops group.
TABLE 4. THE EFFECT OF CARNOSINE, ASPIRIN AND A COMBINATION OF BOTH EYE DROPS ON SOLUBLE PROTEIN, THIOL CONTENT, AND THE ACTIVITIES OF
GPX, CAT, AND GR IN THE LENS.
Group n Protein (g/l) Thiol (mg/gl protein) GPx (U/g protein) CAT (U/g protein) GR (U/g protein)
A 12 10.46±0.69 118.13±24.36 17.28±5.19 75.61±24.75 3.81±2.15
B 11 8.19±1.08* 90.08±18.73* 46.14±4.77* 42.12±10.16 2.75±1.24
C 10 8.53±0.91* 97.95±22.11* 31.31±5.06*# 68.69±21.97 3.66±0.84
D 11 8.63±0.50* 92.38±7.18* 34.38±4.64*# 63.23±25.60 3.23±1.65
E 7 8.90±0.84* 100.89±13.56 26.21±6.99*#** 43.23±9.82 3.63±1.61
The data are mean±SD. “n” was the numbers of the animals in each group. The asterisk indicates significantly different from
Group A; p<0.05. The sharp (hash mark) indicates significantly different from Group B; p<0.05. The double asterisk indicates
significantly different from Group D; p=0.001. Row A was the normal control group, row B was the diabetic rats untreated
group, row C was the diabetic rats treated with carnosine eye drops (1% only) group, row D was the diabetic rats treated with
aspirin eye drops (0.05% only) group, and row E was the diabetic rats treated alternately with carnosine (1%) and aspirin (0.05%)
eye drops group.
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2134transplantation, the long-term complications of diabetes, such
as cataract, remain serious problems. Various mechanisms
have been proposed to explain the pathophysiology of diabetic
complications.  These  mainly  include  oxidative  stress,
increased polyol pathway or osmotic stress, and increased
formation of advanced glycation end products [36].
Although there is cross talk between these pathways,
results in several studies suggest that glycation and oxidative
stress  contribute  the  major  determinants  in  diabetic
complications [36,38,39]. Many drugs have been used for
anticataract research in animals [1,4,12,13,37,40], and some
have proven effective in the prevention of lens opacification
[4,14-16,18,25].
Carnosine was the first and the most simple example of
an active peptide used to prevent diabetic complications. It
has recently attracted much attention as a naturally occurring
antioxidant and transition-metal ion sequestering agent. The
anti-ageing  effect  of  carnosine  had  been  demonstrated  in
many studies in vivo and in vitro [19-23,41]. In our previous
study,  there  was  some  evidence  verifying  the  effect  of
carnosine on preventing cataract development [18]. Through
its distinctive combination of antioxidant and anti-glycating
properties, carnosine is able to attenuate cellular oxidative
stress and can inhibit the intracellular formation of reactive
oxygen  species  and  reactive  nitrogen  species  [42].  By
controlling glycation, oxidative stress, and by chelating metal
ions, carnosine is able to reduce harmful sequelae such as
DNA  damage  [42].  Therefore,  the  effect  of  carnosine  on
delaying  cataract  formation  may  be  through  preventing
glycation and oxidation, thus protecting protein and DNA
against cross-linking and other damage.
Figure 7. Photographs of the stages of cataract from stage 0 to stage
3 in our study.
In our present study, the activity of GPx was raised in
diabetes and this was partly normalized by carnosine. If the
rise can be considered as a reaction to oxidative stress then
presumably carnosine decreased this stress. CAT and GR
appeared to be decreased in the untreated diabetic rats, but less
so  in  the  treated  diabetic  rats,  however  there  were  no
statistically significant differences.
Carnosine eye drops, on mice, rats, rabbits, and dogs were
well tolerated at both total and local levels [43]. In animals
the eye drops did not affect the diameter of the pupil, nor did
they increase intraocular pressure. In our study, eye irritation
was not noticed [18]. Thus, this dose of carnosine used as eye
drops is safe.
Forty  years  ago,  Cotlier  [44]  reported  that  aspirin
(acetylsalicylic  acid)  could  protect  patients  with  diabetes
mellitus against cataract. Experimental studies then showed
that  aspirin  protected  lens  proteins  against  a  variety  of
chemicals relevant to cataract formation [17,45-48]. In those
experiments,  aspirin  delayed  experimental  cataract  in
laboratory animals by decreasing glycation of lens proteins,
and a fall in glutathione levels. The loss of enzyme activity,
such as GR, induced by diabetes was also alleviated by aspirin
[15,48,49].  The  decrease  in  glutathione  and  the  related
enzymes, and the increase in glycation were related to the
progression of lens opacification. In the present study, levels
of thiol were decreased in the lenses of rats receiving the
aspirin eye drops, and the results supported the viewpoint
reported  above.  It  has  been  shown  that  aspirin  reduced
Figure 8. The effect of carnosine, aspirin and a combination of both
eye drops on STZ-induced cataract rats at the 8th week. In the
calculation of the incidence of lenses in various stages, total lenses
in a group were considered to be 100%. Panel A was the normal
control group, panel B was the diabetic rats untreated group, panel C
was the diabetic rats treated with carnosine eye drops (1% only)
group, panel D was the diabetic rats treated with aspirin eye drops
(0.05%  only)  group,  and  panel  E  was  the  diabetic  rats  treated
alternately with carnosine (1%) and aspirin (0.05%) eye drops group.
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2135glycation in experimental animals by acetylation of amino
groups.
Therefore, we considered whether the combination of
carnosine and aspirin eye drop treatment might increase the
benefits  of  preventing  cataract  development.  The  present
results showed that the combination treatment delayed the
progression of diabetic cataract in rats. The decrease in soluble
protein content in the diabetic group lenses compared with
lenses  in  the  normal  group  could  be  partly  due  to
insolubilization of proteins and perhaps some leakage. The
combination  treatment  not  only  mitigated  the  decrease  in
water-solution proteins but also mitigated the decrease in thiol
levels, and the increase in activity of GPx, some more than
other  treatments.  Furthermore,  the  effect  of  combination
treatment was greater than carnosine or aspirin eye drops
alone  in  preventing  the  thiol  and  related  enzyme  levels,
involving the formation of diabetic cataract. It is possible that
the  delay  of  STZ-induced  cataract  by  the  combination
treatment is partly due to a synergism of carnosine and aspirin.
Carnosine  preferentially  reacts  with  sugars  to
competitively inhibit the glycation of lysine in crystallins. The
presence of carnosine inhibits the generation of crosslinked
protein, the disappearance of crystallins, and the production
of low-molecular-weight species. It is conceivable, therefore,
that carnosine can react with polypeptide carbonyl groups,
irrespective of their mode of generation, to form protein-
carbonyl-carnosine adducts in vivo via a process that might
be termed protein “carnosinylation” [50]. Aspirin decreased
glycation in vitro [46,51] and in vivo in rats [48,52] and also
partly maintained GSH levels in the lenses of streptozotocin-
induced diabetic rats [18,52]. This protective action appears
to be brought about by acetylation of vulnerable groups of lens
proteins [53,54], and then, acetylation of a single lysine in
human  crystallin  was  identified  [55].  Our  present  study
suggested  that  carnosine,  competitively  inhibiting  the
glycation  of  lysine,  and  aspirin,  acetylating  lysine  in
crystallins, are synergistic.
Furthermore,  if  carnosine  and  aspirin  eye  drops
influenced different changes in STZ-induced hyperglycemia,
then a combination of two anti-cataractous drugs could be
more effective than either of them alone. Hence, we designed
the study to investigate the role of a combination of carnosine
and aspirin eye drops in the prevention or delay of STZ-
induced diabetic cataract. It is the first time that carnosine eye
drops and aspirin eye drops alternately have been used for
protecting or delaying diabetic cataract. In the present study,
treatment  with  carnosine  and  aspirin  eye  drops,  and  the
combination of both, all delayed the onset and progression of
cataract. The above notion was supported by finding that the
combination was better than aspirin alone in delaying the
progression of lenticular opacity.
Eye drops are better modalities than oral treatment for
safety and convenience. The present concentration of eyes
drops were based on previous studies [18]. According to our
previous experience, the dose of eye drops was chosen to
provide equivalent levels of each drug to the lens, and the dose
volume was increased along with the increase of body weight.
To overcome the limitation of the volume applied by a single
dosage  to  rat  eyes,  we  increased  the  frequency  of
administration to sustain the dose volume [18,25]. Therefore,
we made carnosine drop solutions to 1mg/ml (0.1%), applied
twice a day and the aspirin drop solution to 0.5 mg/ml (0.05%),
twice  daily.  Note  that  the  combination  treatment  in  fact
provided only half the amount of carnosine or aspirin as the
separate drug treatment regimes.
Interestingly, the combination was more effective than
carnosine alone in maintaining levels of thiol and the related
enzyme activities, even though the effect of carnosine eye
drops were better on delaying the stage of cataract. And the
effects of combination eye drops were better than aspirin eye
drops on delaying the progression of cataract. These results
thus provide a clue, for the first time, that combination eye
drops  may  have  the  more  significant  effect  to  delay  the
progression of diabetic cataract.
In conclusion, a combination treatment of carnosine and
aspirin eye drops administered alternately twice a day, can
inhibit cataract formation and progression in a STZ-diabetic
animal  model.  The  combination  treatment  is  better  than
aspirin treatment alone; and in the alteration of biochemical
indicators,  better  than  carnosine  treatment.  Therefore,  the
treatment of diabetic cataract, with a combination of carnosine
and aspirin eye drops, merits further attention.
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